Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Original Research
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 16,173 | Dovepress* | 12,077+ | 1,859 | 13,936 | |
| PubMed Central* | 4,096 | 1,040 | 5,136 | ||
| Totals | 16,173 | 2,899 | 19,072 | ||
| *Since 13 February 2017 | |||||
View citations on PubMed Central and Google Scholar